Sales expected upon successful performance evaluation and validation

August 24, 2017 07:30 AM Eastern Daylight Time

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that they have strengthened relationships with key regional customers throughout the Caribbean basin to purchase the Company’s Zika virus diagnostic.

The potential customer base includes laboratories, regional health ministries, and hospitals interested in offering a state-of-the-art molecular diagnostic for the Zika virus to their customers, citizens, and patients. To date, Company representatives and future product distributors have conducted on-site suitability assessments at dozens of locations in countries across the region, with the understanding that these locations would be among the first to have access to the Zika virus test upon completion of successful performance evaluation and validation studies. The Company is also an approved reseller of diagnostic equipment, to enable upgraded laboratory facilities for those locations who have not previously been able to offer molecular diagnostics.

Dwight Egan, Co-Diagnostics CEO, remarked, “Molecular diagnostics are the internationally recognized gold standard in disease detection, and Co-Diagnostics’ assays are built on our own platform without expensive royalty payments built in to the cost. We are uniquely positioned to assist the many overlooked and underserved populations in this region interested in a competitively priced, high quality diagnostic tool to assist in the detection of the Zika virus.”

About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements: This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Disclaimer: This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts

About Co-Diagnostics

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our molecular diagnostics development platform is marketed under the brand name Co-Dx™. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.